Skip to main content
OpenTrials
Completed

NCT Number: NCT04379297

COvid-19 National Survey for Assessing VIral Spread by Nonaffected CarriErs (CON-VINCE)

CON-VINCE (COvid-19 National survey for assessing VIral spread by Non-affected CarriErs) is a national, monocentric, and longitudinal study aiming to evaluate the spread dynamics of the COVID-19 disease within the Luxembourgish population. Participants who are clinically asymptomatic or present with only mild symptoms will be followed up longitudinally, regularly tested for SARS-CoV-2 by RT-PCR, antibody status, and subjected to an epidemiological, clinical and biological phenotyping to better understand the nature, dynamics of infectivity and spread of the virus in the population. CON-VINCE will also track the psychological and socio-economic impact of long-term containment measures on the general population.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Luxembourg Institute of Health

Strassen, 1445, Luxembourg

About this study

To capture the dynamics and impact of the virus spread in the Luxembourgish population, data and sample collection is done every two weeks for two months (4 times in total) with a final follow-up one year after the participant's inclusion in the study. Participants complete questionnaires before each sample collection. The baseline questionnaire captures demographic data, medical history, behavioral and psychological data, and socio-economic status. Participants provided information on medical history, history of allergies, smoking, and chronic medication taken regularly. COVID-19-related data and environmental conditions of the household were obtained.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Subjects aged 18 and older of both genders, with a full capacity of consent.
  • SARS-CoV-2-positive individuals with an asymptomatic or oligosymptomatic infection (mild or oligosymptomatic disease course is defined as absence of fever and respiratory distress or cough not attributable to other known chronic disease).
  • OR SARS-CoV-2-negative individuals at the time of inclusion.
  • OR post-infectious SARS-CoV-2-negative individuals with acquired immunity to SARS-CoV-2 and a mild disease course.

Exclusion criteria

  • Evolution of the COVID-19 disease requiring a hospital admission before inclusion in the study
  • Presence of fever and respiratory distress/cough at the time of inclusion not attributable to other known chronic disease

Treatment and study plan

Primary outcomes

  1. Prevalence and dynamics of the SARS-COV 2 infection in Luxemburg

    Time frame: 04.2020-05.2021

    Evaluation of the prevalence by RT-PCR and serology testing

  2. Collection of samples for research

    Time frame: 04.2020-05.2021

    Samples will be analysed and stored for future research

Secondary outcomes

  1. Psycho-social evaluation

    Time frame: 04.2020-05.2021

    Psychological and socio- economic impact of long-term containment measures on the general population

Sponsors and collaborators

Lead sponsor

Luxembourg Institute of Health

Other Gov

Collaborators

  • BioneXt Lab
  • Centre Hospitalier du Luxembourg
  • Ketterthill
  • Laboratoire National de santé
  • Laboratoires Réunis
  • Luxembourg National Research Fund
  • TNS-Ilres
  • University of Luxembourg

Registry information

Acronym: CON-VINCE

Important dates

Study start
2020
Primary completion
2021
Study completion
2022
First posted
May 7, 2020
Registry last updated
Aug 14, 2024

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.